Im­mu­nic’s stock falls on mul­ti­ple scle­ro­sis da­ta; En­tra­da’s lay­offs

Plus, news about Hen­lius, San­doz, Cel­lec­tar Bio­sciences, Ono Phar­ma and Al­tami­ra Ther­a­peu­tics:

Im­mu­nic’s Phase 2 mul­ti­ple scle­ro­sis read­out: The com­pa­ny

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER